rMark Bio, a Chicago, IL-based leader in the application of AI to accelerate innovation, collaboration, and scientific discovery for the life sciences industry, received an investment from CerraCap Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to continue to expand its global presence.
Led by Jason Smith, Co-founder and CEO, rMark Bio provides a proprietary deep learning platform that analyzes global healthcare data in-conjunction with internal clinical research data to optimize partnership and engagement strategies across the life-cycle of a product for healthcare industries including pharmaceutical, academic institutions, medical device companies, and investment firms. By leveraging its platform, organizations can reduce time and cost of data analysis while increasing opportunities to align real-time business strategies between their R&D, Product, Commercialization and external teams
The company provides artificial intelligence services to the top 20 pharmaceutical companies globally and has partnered with industry-leading technology and healthcare organizations.